Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide is indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

unichem pharmaceuticals (usa), inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - irbesartan 150 mg - irbesartan and hydrochlorothiazide tablets, usp are indicated for the treatment of hypertension. irbesartan and hydrochlorothiazide tablets, usp may be used in patients whose blood pressure is not adequately controlled on monotherapy. irbesartan and hydrochlorothiazide tablets, usp may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. the choice of irbesartan and hydrochlorothiazide tablets as initial therapy for hypertension should be based on an assessment of potential benefits and risks. patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. the decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving g

Australija - engleski - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - hydrochlorothiazide,irbesartan -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - hydrochlorothiazide,irbesartan -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - hydrochlorothiazide,irbesartan -

Australija - engleski - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 300 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; lactose monohydrate; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 150 mg - tablet - excipient ingredients: povidone; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

viteia pty ltd - irbesartan, quantity: 75 mg - tablet - excipient ingredients: croscarmellose sodium; lactose monohydrate; povidone; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 4000 - irbesartan mylan is indicated for the treatment of hypertension., irbesartan mylan is indicated for delaying the progression of renal disease in hypertensive type ii diabetics with persistent micro-albuminuria (> 30 mg per 24 hours) or urinary protein in excess of 900 mg per 24 hours.

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

remedyrepack inc. - irbesartan (unii: j0e2756z7n) (irbesartan - unii:j0e2756z7n) - hypertension irbesartan tablet usp is indicated for the treatment of hypertension. it may be used alone or in combination with other antihypertensive agents.  nephropathy in type 2 diabetic patients irbesartan tablet usp is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (>300 mg/day) in patients with type 2 diabetes and hypertension. in this population, irbesartan tablet usp reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) (see clinical pharmacology : clinical studies ). irbesartan tablet usp is contraindicated in patients who are hypersensitive to any component of this product.  do not co-administer aliskiren with irbesartan tablet usp in patients with diabetes (see precautions, drug interactions).

Kanada - engleski - Health Canada

pharmascience inc - irbesartan; hydrochlorothiazide - tablet - 150mg; 12.5mg - irbesartan 150mg; hydrochlorothiazide 12.5mg - angiotensin ii receptor antagonists